GvHD Patients
Jun 23, 2023
Graft-Versus-Host Disease (GvHD) Treatment Market: A Moving Target For Therapies
Allogeneic HSCT is a mainstay for patients with different hematological malignancies, but it requires immunosuppressive strategies before and after HSCT. However, approximately half (50%) of the patients receiving allogeneic hematopoietic stem cell transplantation (HCT) from a human leukocyte antigen (HLA)-matched ...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
